Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Fluorouracil + OBP-801|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Fluorouracil||Adrucil||5-FU||Chemotherapy - Antimetabolite 11||Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent, which interferes with DNA and RNA synthesis thereby preventing cancer cell growth and is FDA approved for colorectal, breast, stomach, and pancreatic cancer (FDA.gov).|
|OBP-801||YM753|YM-753||HDAC Inhibitor 38||OBP-801 (YM753) is a histone deacetylase inhibitor belonging to the cyclic peptide class, which may induce both cell cycle arrest and apoptosis (PMID: 18292931, PMID: 23900601, PMID: 32277670).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||esophagus squamous cell carcinoma||not applicable||Fluorouracil + OBP-801||Preclinical||Actionable||In a preclinical study, OBP-801, in combination with 5-FU and radiation, enhanced growth inhibition of esophageal squamous carcinoma cells in culture (PMID: 24854104).||24854104|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|